REFERENCES
- Angastiniotis M, Modell B. Global epidemiology of hemoglobin disorders. Ann NY Acad Sci. 1998;850:251–269.
- Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ. 2008;86(6):480–487.
- Weatherall DJ. The inherited diseases of hemoglobin are an emerging global health burden. Blood. 2010;115(22):4331–4336.
- Zeng YT, Huang SZ. Disorders of haemoglobin in China. J Med Genet. 1987;24(10):578–583.
- Xu XM, Zhou YQ, Luo GX, The prevalence and spectrum of α and β thalassaemia in Guangdong Province: implications for the future health burden and population screening. J Clin Pathol. 2004;57(5):517–522.
- Zhao ZM, Yao LQ, Fan LM, Epidemiological study on thalassemia among the children of 0–7 years old among the six ethnic groups in Xishuangbanna and Dehong of Yunnan province. Chin J Epidemiol. 2011;32(4):352–356.
- Bravo-Urquiola M, Arends A, Gómez G, et al. Molecular spectrum of β-thalassemia mutations in the admixed Venezuelan population, and their linkage to β-globin gene haplotypes. Hemoglobin. 2012;36(3):209–218.
- Higgs DR, Engel JD, Stamatoyannopoulos G. Thalassaemia Lancet. 2012;379(9813):373–383.
- Subspecialty Groups of Hematology, Society of Pediatrics, Chinese Medical Association, Editorial Board of Chinese Journal of Pediatrics. Guidelines for the diagnosis and treatment of β-thalassemia major. Chin J Pediatr. 2010;48(3):186–189.
- Fang JP, Xu LH. Standardization of diagnosis and treatment for children with β-thalassemia major. Chin J Pediatr. 48(3):166–169.
- Rund D, Rachmilewitz E. β-Thalassemia. N Engl J Med. 2005;353(11):1135–1146.
- Rachmilewitz EA, Giardina PJV. How I treat thalassemia. Blood. 2011;118(13):3479–3488.
- Li LY, Li Q, Song LL, The value of MCV, MCH and Hb A2 in laboratory screening of thalassemia. Chin J Obstet Gynecol. 2012;47(2):96–100.
- Li CG, Li CF, Li Q, Li M. Thalassemia incidence and treatment in China with special reference to Shenzhen City and Guangdong Province. Hemoglobin. 2009;33(5):296–303.
- Patrinos GP, Giardine B, Riemer C, et al. Improvements in the HbVar database of human hemoglobin variants and thalassemia mutations for population and sequence variation studies. Nucleic Acids Res. 2004;32(Database issue):D537-541 (http://globin.cse.psu.edu).
- Yan T, Cai R, Mo O, Incidence and complete molecular characterization of glucose-6-phosphate dehydrogenase deficiency in the Guangxi Zhuang autonomous region of southern China: description of four novel mutations. Haematologica. 2006;91(10):1321–1328.
- Liao C, Pan M, Han J, Early prenatal diagnosis of thalassemia: the first report of experience in mainland China. Hemoglobin. 2011;35(4):434–438.
- Deng J, Peng WL, Li J, Successful preimplantation genetic diagnosis for α- and β-thalassemia in China. Prenat Diagn. 2006;26(11):1021–1028.
- Madgwick KV, Yardumian A. A home blood transfusion programme for β-thalassaemia patients. Transfus Med. 1999;9(2):135–138.
- Yin XL, Wu ZK, He YY, Zhou TH, Zhou YL, Zhang XH. Treatment and complications of thalassemia major in Guangxi, Southern China. Pediatr Blood Cancer. 2011;57(7):1174–1178.
- Xu LH, Fang JP, Weng WJ, Huang K, Zhang YT. Autoimmune hemolytic anemia in patients with β-thalassemia major. Pediatr Hematol Oncol. 2012;29(3):235–240.
- Cheng CK, Lee CK, Lin CK. Clinically significant red blood cell antibodies in chronically transfused patients: a survey of Chinese thalassemia major patients and literature review. Transfusion. 2012;52(10):2220–2224.
- Zhou XZ, Zhang MF, Yi YZ, Liu K. Infuence of therapy compliance on the prognosis of children with thalassemia major. Chin J Prac Nurs. 2008;24(6):4–7.
- Tanner MA, Galanello R, Dessi C, A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007;115(14):1876–1884.
- Gao HY, Li Q, Chen JJ, Curative effects and safety of deferasirox in treatment of iron overload in children with β-thalassemia major. Chin J Contemp Pediatr. 2011;13(7):531–534.
- Xu LH, Fang JP, Zhang YT, Clinical analysis of MRI*T2 tests on iron overload in patients with β-thalassemia major. Chin J Obstet Gynecol Pediatr. 2011;7(5):430–433.
- Telfer P. Update on survival in thalassemia major. Hemoglobin. 2009;33(1):S76–S80.
- Gaziev J, Lucarelli G. Hematopoietic stem cell transplantation for thalassemia. Curr Stem Cell Res Ther. 2011;6(2):162–169.
- Fang JP, Xu LH. Hematopoietic stem cell transplantation for children with thalassemia major in China. Pediatr Blood Cancer. 2010;55(6):1062–1065.
- Lucarelli G, Galimberti M, Polchi P, Bone marrow transplantation in patients with thalassemia. N Engl J Med. 1990;322(7):417–421.
- Fang JP, Xu LH, Yang XG, Wu YF, Weng WJ, Xu HG. Panel reactive antibody in thalassemic serum inhibits proliferation and differentiation of cord blood CD34+ cells in vitro. Pediatr Hematol Oncol. 2009;26(5):338–344.
- Xu HG, Fang JP. Hematopoietic stem cell transplantation in β-thalassemia major. J China Pediatr Blood Cancer. 2012;17(2):49–56.